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Abstract
A tobacco mosaic virus (TMV)-based vector was utilized for expression of a cytosolic form of the bovine herpesvirus type 1 (BHV-1)
protein glycoprotein D (gDc). Nicotiana benthamiana plants were harvested 7 days after inoculation with RNA transcripts derived from
the TMV-gDc recombinant virus. Recombinant gDc protein of expected electrophoretic mobility accumulated in inoculated leaves to
a concentration of about 20g/g of fresh leaf tissue. Oil-based vaccines were formulated with crude foliar extracts to immunize mice
parentally. After a single injection, animals developed a sustained and specific response to both the isolated gD and native virus particles.
Cattle vaccinated with the same gDc containing extracts developed specific humoral and cellular immune responses directed against both
the viral gD and BHV-1 particles. Most importantly, animals vaccinated with the plant-produced gDc showed good levels of protection
after challenge with the virulent BHV-1. Virus excretion was drastically reduced in these animals, reaching levels comparable to animals
vaccinated with a commercial BHV-1 vaccine. The positive immunological characterization obtained for the gDc, indicated that an
important part of the natural conformation was retained in the plant recombinant protein.
© 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
Plants represent one of the most abundant biomass
sources for large-scale production of biological products.
Several reviews on the application of this technology argue
that it offers cost efficiency over more expensive fermenta-
tion or cell culture based methods [1–3]. Particularly in the
vaccine field, several publications reported the development
of transgenic plants expressing successful immunogens for
oral or parenteral immunization [4–7]. Foreign proteins can
also be produced in plants by transient expression using
∗ Corresponding author. Present address: Depto. Biotecnologı´a,
INIA-Madrid, Ctra. A Coruña Km.7, Madrid 28040, Spain.
Tel.: +34-91-347-6893; fax: +34-91-357-3107.
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plant virus-based vectors [8]. The ability of these vectors to
achieve transient expression of a foreign gene product has
some advantages over constitutive expression from a trans-
genic plant. Most notable is the fact that products of interest
can be produced very rapidly after inoculation of mature
plants with the additional benefit that the recombinant pro-
teins can accumulate to high levels without appreciable
degradation or toxic effects on the plant. Plant viral-based
vectors have been successfully produced from a variety of
plant RNA viruses and can be generally classified in those
that can display foreign peptides fused to the coat proteins
on the surface of viral particles [9] and those that are able
to express whole recombinant proteins that accumulate
within the plant, independently from other vector proteins
[10]. Tobacco mosaic virus (TMV)-based expression vec-
tors represent one of the more successful examples of this
technology [11] and have been utilized for production of
0264-410X/$ – see front matter © 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/S0264-410X(03)00495-X
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different therapeutic proteins, such as -trichosanthin [12]
and tumor-specific single-chain antibodies [13]; and vaccine
antigens, such as a malarial peptide [14] and the VP1 struc-
tural protein from foot-and-mouth disease virus (FMDV)
[15]. We report here the use of the TMV-30B vector [16]—
which typifies a relatively stable family of TMV-based
protein expression vectors—for the production in plants of
a protein from bovine herpesvirus type 1 (BHV-1).
BHV-1 is the causative agent of a group of respiratory and
reproductive disorders in cattle that is commonly referred to
as infectious bovine rhinotracheitis [17]. The disease affects
both adult and young animals and is of significant economic
importance worldwide. Usual symptoms include rhinotra-
cheitis, infectious pustular vulvovaginitis, enteritis, general
respiratory disease and encephalitis, decreased milk produc-
tion, weight loss and abortion in pregnant cows [18]. The
BHV-1 vaccines in current use are formulated with either
inactivated or modified live virus and both have a number of
disadvantages. The inactivated vaccines are often poor im-
munogens and they have been shown to cause clinical dis-
ease if they are insufficiently inactivated [19]. Alternatively,
live vaccines may induce immunosuppression [20] and com-
plicate the process of discerning between vaccinated and in-
fected animals. Alternative vaccination strategies involving
the use of individual viral components such as glycoprotein
D (gD) to induce protective immune responses to BHV-1
have been explored to overcome these problems [21–24].
In this report, the TMV-30B vector was utilized to pro-
duce a truncated form of the BHV-1 gD (cytosolic or gDc)
protein in plants. Crude extracts of leaves inoculated with
the recombinant virus were used to parentally immunize
mice and cattle. We were able to show that these plant ex-
tracts induced both humoral and cellular-specific responses
that recognized both the isolated protein and BHV-1 virus
particles. Our results also demonstrated that the recombi-
nant gDc could be stably produced in plants and that it re-
tained antigenic integrity. More importantly, we showed that
crude plant extracts containing the gDc protein had sufficient
Fig. 1. Schematic structure of the TMV-gDc vector. The figure shows the location of the TMV-derived genes in the vector (the RNA-dependent RNA
polymerase (replicase), the movement protein (mp) and the coat protein (cp)) and the gDc insert (1.05 kb) located between the PacI and PmeI sites in
the polylinker sequence. Subgenomic promoters are indicated as arrows upstream of the corresponding genes as is the location of the T7 promoter and
key restriction sites.
immunogenic potential to induce protection in the natural
host against viral challenge.
2. Materials and methods
2.1. Construction of the TMV-based expression vector
carrying BHV-1 gDc
The recombinant TMV-gDc vector was obtained from
a variant of the TMV-30B expression vector [16] kindly
provided by Dr. W.O. Dawson. Cloning of the foreign se-
quence into the TMV vector was as previously described
[15]. The gDc sequence corresponding to nucleotides 54
through 1079 of the full-length gD was obtained by PCR
from a pGem plasmid carrying the BHV-1 gIV gene.
The primers, gDc-PacI, (5′-ATTAATTAATGAGCTTG-
CCTACACCCGCGCCG-3′) and gDc-PmeI (5′-GTTTAAA-
CTCAGGCGTCGGGG GCCGCGGG-3′), were used to
introduced start and stop codons at the extremes of the
gDc sequence along with PacI and PmeI restriction sites,
respectively. The resulting fragment was then digested with
PacI and PmeI and inserted in the polylinker sequence of
the TMV vector (Fig. 1). Integrity and correct insertion
of the gDc sequence into the TMV-30b vector were con-
firmed by restriction analysis and nucleotide sequencing.
The TMV-gDc plasmid was linearized by digestion with
PstI and used as DNA template for the in vitro production
of the infectious viral capped RNA following manufac-
turer instructions (Amplicap T7 transcription Kit, Epicentre
Technology). Nicotiana benthamiana plants were mechani-
cally inoculated on the upper surface of mature leaves using
infectious RNA transcripts diluted in buffer containing 1%
Na-pyrophosphate (pH: 9.0), 1% celite and 1% bentonite.
Plants were kept in growth chambers (16 h per day of light,
30 ◦C day temperature, 24 ◦C night temperature) until har-
vested. Inoculated foliar material was stored at −20 ◦C until
utilized.
D.M. Pe´rez Filgueira et al. / Vaccine 21 (2003) 4201–4209 4203
2.2. Western blot analysis of the TMV-gDc infected
leaves
Western blot analyses were performed on extracts
from inoculated leaves using a polyclonal mouse anti-
serum specific for a recombinant gD produced in Es-
chirichia coli (gD-Ec) [25]. Leaves were harvested at
7 days post-inoculation (dpi) and total protein was ob-
tained from inoculated leaves by an organic extraction
protocol following the manufacturer instructions (Tripure,
Roche). The extracted proteins were separated in a 12.5%
SDS polyacrylamide gel (PAGE) and transferred onto an
ECL nitrocellulose membrane (Amersham). The mem-
branes were blocked overnight with phosphate saline buffer
(PBS)-Tween 20 (PBST), 4% skim milk (blotto buffer) and
incubated with a polyclonal mouse antiserum specific for
the gD-Ec. Blots were then incubated with a HRP-labeled
anti-mouse IgG antibody (Amersham) and developed with
X-film (Kodak) using the ECL Western blotting detection
system (Amersham). Concentration of the recombinant
proteins was estimated from blots in a Biorad Fluor S
MultiImager System using the Quantity One 4.0 software
(BioRad).
2.3. Animal immunizations
2.3.1. Mice
Male BALB/c mice (6–8 weeks old) were used for
vaccination. Animals received a single dose of an oil-based
vaccine formulated with incomplete Freund adjuvant (IFA)
by the intra-peritoneal (i.p.) route. Fresh plant tissue was
macerated in the presence of liquid nitrogen, resuspended
phosphate saline buffer (PBS) pH 7.5 and emulsified in the
oily phase. Mice received 0.2 ml of this vaccine containing
1 g of fresh leaf tissue/ml. A control group of animals were
also vaccinated with 0.2 ml of a conventional oil BHV-1
vaccine (conv. vac.) formulated in IFA and containing inac-
tivated BHV-1 with a previous titer of 107.5 tissue-culture
infective dose 50% (TCID50)/ml. Animals were bled at
different times post-vaccination.
2.3.2. Cattle
Twelve to fourteen-month-old Holstein and Angus ×
Hereford cows were utilized in the immunization exper-
iments. Animals were selected based on their negative
serology for BHV-1. Cattle were immunized at days 0,
21, 45, 70, 120, 150 and 195 using 5 ml of a similar
vaccine as described for mice. Half of the dose was in-
jected by the intra-muscular (i.m.) route and the other
half was injected subcutaneosly (s.c.). Positive control
animals were immunized using 5 ml of the conventional
BHV-1 vaccine, formulated with inactivated virus and
further revaccinated 3 weeks later with the same im-
munogen. Serum samples were extracted from peripheral
blood at different time-points after the initial inocula-
tion.
2.4. Analysis of antibody response to plant-expressed
gDc protein
Serum samples from mice and cattle inoculated with the
plant-derived gDc were tested by Western blot and ELISA
for reactivity against different BHV-1 antigens.
2.4.1. Western blot
Recombinant gD-Ec proteins were applied to a 12.5%
SDS-PAGE, blotted onto an Immobilon P (Millipore) mem-
brane and then incubated overnight in blotto buffer at 4 ◦C.
The next day, membranes were washed and incubated for
2 h at 37 ◦C with serum samples from immunized cattle di-
luted 1/20 in the same buffer. Blots were washed again and
then incubated with an AP-labeled anti-bovine Ig guinea
pig antiserum (Dakkopats) for 1 h at 37 ◦C. After extensive
washing the reaction was developed by the addition of the
NBT/BCIP substrate.
2.4.2. ELISA for gD-specific antibodies
Purified recombinant gD-Ec diluted in 0.1 M carbonate–
bicarbonate buffer pH 9.6 (0.875g per well) was adsorbed
to Immulon II plates (Dynatech) by overnight incubation
at 4 ◦C. Plates then were blocked with PBS-Tween 20 1%
gelatin (blocking buffer) and subsequently incubated for
1 h at 37 ◦C with mice serum samples and then a sec-
ondary anti-mouse-Ig-specific HRP-conjugated antibody
(KPL). Primary and secondary antibodies were diluted
with the same blocking buffer. The reaction was developed
by addition of o-phenylenediamine (1,2-benzenediamine)
dihydrochloride-H2O2 in phosphate–citrate buffer pH 4.5
and read 3 min later at 490 nm in an MR 500 Microplate
Reader (Dynatech). Titers were expressed as log 10 of the
reciprocal of the highest serum dilution which gave opti-
cal density (OD) readings of at least twice a pool of sera
from three animals immunized with extracts of plants in-
oculated with the empty vector (TMV-30B) at the same
dilution.
2.4.3. ELISA for BHV-1-specific antibodies
Immulon I plates (Dynatech) were incubated overnight
at 4 ◦C with partially purified BHV-1 diluted in 0.1 M
carbonate–bicarbonate buffer pH 9.6, as described be-
fore [18]. The next day, plates were blocked for 1 h with
PBST 1% egg albumin, and mice or cattle serum samples
were then incubated for 30 min at 37 ◦C. After wash-
ing, anti-mice-Ig or bovine-Ig-specific HRP-conjugated
antibodies were diluted in the same blocking buffer,
added to the plates and incubated for 30 min at 37 ◦C.
The reaction was developed at room temperature by ad-
dition of 2,2′-azino-bis(3-ethylbenz-thiazoline-6-sulfonic
acid)-H2O2 in citrate buffer pH 5 and the OD at 410 nm was
measured 20 min later in an MR 500 Microplate Reader
(Dynatech). Titers for mice serum samples were calculated
as described for the gD-specific ELISA. Titers for bovine
sera were expressed as log 10 of the reciprocal of the highest
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serum dilution which gives OD readings 40% above a pool
of sera (diluted 1:2560) from BHV-1 vaccinated animals.
2.5. BHV-1 production and purification
BHV-1 strain Los Angeles (LA) was propagated in Madin
Darby bovine kidney (MDBK) cells grown in Eagle’s Mini-
mal Essential Medium supplemented with 10% foetal bovine
serum (FBS; Gibco). Confluent monolayers were inoculated
with BHV-1 at a multiplicity of infection of 0.1 and the virus
was allowed to adsorb for 45 min at 37 ◦C before the addi-
tion of fresh culture medium. After a cytopathogenic effect
(CPE) was observed, the supernatant was collected and cel-
lular debris was removed by centrifugation at 3000 × g for
30 min. For vaccine formulation, virus was diluted to 107.5
tissue-culture infective dose 50% and then inactivated with
BEI [18]. For ELISA, supernatants were pelleted by ultra-
centrifugation at 120,000 × g for 1 h at 4 C. For in vitro
lymphoproliferation assays, virus suspensions were diluted
to 105 TCID50/ml, stored at −70 ◦C and immediately before
use, inactivated by UV light exposure for 1 min at 11 cm
from the source (General Electric G875 UV bulbs).
2.6. In vitro lymphoproliferation assay
Blood samples were collected by venipuncture with
syringes containing heparin. Lymphocyte-enriched cells
were isolated from the buffy coats by centrifugation on
LymphoprepTM (density 1.077 g/ml; Nycomed Pharma
A.S). Cells were then washed twice in RPMI 1640 medium
supplemented with 5% of foetal bovine serum and finally
resuspended at a concentration of 2.5 × 106 cells/ml in the
same culture medium with 10% FBS. Inactivated BHV-1
virus antigen was diluted 1:100 in RPMI 1640 medium and
added to the cultures containing 2.5× 105 lymphocytes per
well, reaching a final volume of 200l per well. Lympho-
cytes were incubated for 4 days at 37 ◦C in a humidified
atmosphere with 5% CO2. Cell proliferation was measured
by addition of 0.4Ci [3H]thymidine per well 20 h before
harvesting. Each test was performed in triplicate. Thymidine
uptake for each culture was determined in a liquid scintilla-
tion counter (LKB, Wallac, 1219 Rackbeta), and arithmetic
means and standard deviations were calculated for triplicate
values. Results were obtained as mean counts per minute
(cpm) and expressed as stimulation index (SI = mean cpm
of cultures in the presence of BHV-1 antigen/mean cpm of
cultures without BHV-1 antigen). The threshold value was
established at SI = 3.
2.7. Challenge experiments
Animals were challenged at 210 dpi using BHV-1
virus (LA strain) suspended in Eagle’s medium at a con-
centration of 107.5 TCID50. A volume of 1.5 ml of the
inoculum was administered into each nostril of individual
animals by aerosol exposition using an ultrasonic nebulizer
(Electrolab AP-300). Prior to challenge, animals were
clinically examined, rectal temperature recorded and blood
samples and nasal swabs were collected to establish baseline
values. Nasal swabs were obtained by inserting tampons
into the ventral meatus of the nasal passage and immediately
dipping them in MEM containing 5000 IU penicillin/ml,
2500g streptomycin/ml and 10g amphotericin B/ml.
Samples were collected 2, 4, 5, 7, 9, 11, 12, and 15 days
post-challenge (dpch). For virus detection, serial dilutions
of the nasal fluids were immediately inoculated onto MDBK
cell monolayers cultured in 96 well plates. Monolayers were
inspected for 48 h for the appearance of cytopathological ef-
fect and results were expressed as TCID50/ml of nasal fluid.
Cattle were clinically examined for 15 consecutive days
after challenge and evaluated for the presence of anorexia,
increase of body temperature, rhinitis and vulvovaginitis.
3. Results
3.1. Expression of recombinant gDc in plants
Infective RNA transcripts were synthesized from the
TMV-gDc and TMV-30B plasmids and utilized for inoc-
ulation of N. benthamiana. Infected plants were isolated
in growth chambers and inoculated leaves were harvested
1 week after infection. In order to analyze the produc-
tion of the recombinant gDc, total proteins were extracted,
separated in a 12.5% SDS-PAGE and transferred to a ni-
trocellulose membrane. An equivalent amount of protein
extracted from 6 mg of fresh leaf tissue was loaded for all
of the TMV-gDc, TMV-30B and mock infected samples.
A sample with 50 ng of gD-Ec protein served as a positive
control. Blots were analyzed by a Western assay using a
mouse anti-gD-Ec as the probe. Results in Fig. 2 show the
presence of a positive signal with similar electrophoretic
Fig. 2. Expression of the recombinant gDc protein in plants. Western
blot of plant extracts and recombinant gDc developed using a mouse
polyclonal serum against the gD-Ec. Foliar extracts from mock infected
(lane 1), TMV-30B inoculated (lane 2), and TMV-gDc inoculated (lane
4) plants were blotted together with 0.05g of gD-Ec (lane 3). All plant
samples derived from 6 mg of fresh leaves. Position of protein molecular
weight standards is indicated on the right side of the blot.
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mobility in both TMV-gDc and gD-Ec lanes. The amount of
the recombinant gDc was estimated at about 15–20g/g of
fresh tissue. No signal was detected for the protein extracts
from TMV-30B or mock infected leaves.
3.2. Induction of an anti-BHV-1 response in mice
immunized with crude foliar extracts inoculated
with the TMV-gDc
Mice were immunized using an oil-based vaccine contain-
ing 0.2 g of fresh leaf tissue per dose. Serum samples were
recovered at different times post-immunization with the pur-
pose of measuring reactivity against BHV-1 antigens. The
recombinant gD-Ec was utilized as the antigen in an indirect
ELISA to monitor the titre of anti-gDc antibodies induced in
the mice after injection of the plant extracts. The results in
Fig. 3a and b demonstrate that all animals immunized with a
single dose of the plant-produced gDc developed a specific
and significant humoral response to both gDc and BHV-1,
presenting a kinetic that clearly resembles that of the animal
immunized with a conventional vaccine for up to 80 dpi.
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Fig. 3. Humoral immune response induced by the plant-produced gDc in mice. Titers are expressed as described in Section 2. (a) Samples were tested by
ELISA for presence of anti BHV-1 gD antibodies. Animals were immunized with a conventional BHV-1 vaccine (conv. vac.) or immunogens containing
fresh leaf extracts from plants inoculated with TMV-gDc (gDc1–gDc5). The titers are expressed relative to those of the control animals injected with
TMV-30B, (b) Comparative response to BHV-1 whole particles and gD protein at 70 dpi. Mice were immunized as indicated above and serum samples
were tested by ELISA using either partially purified BHV-1 particles (grey bars) or gD-Ec (black bars) as antigens adsorbed to the plates.
3.3. Anti-BHV-1 humoral immune responses in cattle
immunized with crude foliar extracts inoculated with the
TMV-gDc
Cows serologically negative for BHV-1 were immunized
with single vaccine doses consisting of a total of 5 g of fresh
leaf tissue infected with either TMV-gDc or TMV-30B.
Western blot analysis revealed, after two vaccinations, that
the plant-derived gDc was able to induce a specific anti-
body response in cattle directed against recombinant gD-Ec.
Moreover, the antibody reactivity of the plant-gDc immu-
nized animals was similar to that of a pool of BHV-1 vacci-
nated cattle. As expected, cows inoculated with the control
TMV-30B did not have antibodies that reacted against the
BHV-1-specific bands (Fig. 4). An ELISA using whole virus
as antigen was utilized to evaluate the antibody response di-
rected against whole BHV throughout the experimental pe-
riod. These results confirmed that cattle immunized with the
plant-produced gDc were also able to develop a specific and
significant response against the native antigen (Fig. 5). To
control for possible contact of the test animals with BHV-1
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Fig. 4. Immune response (40 dpi) of cattle inoculated with the recombinant
gDc produced in plants. Sera were tested by Western blot against the
purified gD-Ec. Cows 31 and 39 were immunized with foliar extracts
from TMV-30 infected plants and animals 41 and 49 received extracts
from TMV-gDc infected plants. The positive control represents a pool
of sera from five cows immunized with a conventional BHV-1 vaccine
(conv. vac. #1–5). The arrow indicates the position of the gD-Ec protein.
in the field during the course of the experiment, a commer-
cial ELISA system was used to test the reactivity of all the
animals against the gE antigen of BHV-1 (data not shown).
3.4. Anti-BHV-1 cellular immune responses in cattle
immunized with crude extracts from leaves
inoculated with the TMV-gDc
Lymphocyte samples from PBMC were obtained at
80 dpi from cattle injected with crude foliar extracts from
TMV-gDc and TMV-30B infected plants. An additional
animal inoculated with a commercial vaccine was also
included in the experiment as positive control. In vitro lym-
phoproliferation was measured by assessing the amount of
label incorporated by the cells in the presence of inactivated
BHV-1 particles after 96 h of culture. Lymphocytes from
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Fig. 5. Humoral immune response induced in cattle injected with plant extracts. (a) Serum samples were extracted at different time-points and tested by
ELISA using whole BHV-1 particles as antigen. Primary vaccination and subsequent booster injections (indicated by arrows) were performed using 5 g
of fresh leaf tissue from plants inoculated with TMV-gDc (animals 41 and 49) or TMV-30B (animals 31 and 39).
animals inoculated with the plant-produced gDc exhibited
positive proliferation indexes (mean SI = 3.6 and 7.0)
comparable to the BHV-1 vaccinated cow (mean SI = 4.9).
Cows inoculated with the TMV-30B-infected foliar extracts
presented a mean SI = 1.1, under the threshold for positive
responses (SI = 3.0) (Fig. 6).
3.5. Challenge experiments in cows vaccinated with
TMV-gDc inoculated foliar extracts
Finally, to test for the possible protective effect of the
recombinant vaccines, animals vaccinated with the differ-
ent foliar extracts were challenged with infective BHV-1 at
210 dpi. Protection levels obtained were assessed from the
amount of excreted virus in nasal fluids (Fig. 7). Unvacci-
nated control animals and cows vaccinated with TMV-30B
alone showed similar patterns of virus shedding. Interest-
ingly, virus shedding was delayed up to 5 days in cattle that
received plant extracts containing gDc and virus titers were
reduced between 100 and 10,000 times in these animals.
Moreover, two of the BHV-1 vaccinated animals (conv. vac.
#2 and #4) showed similar and even higher virus excre-
tion titers than the plant-gDc inoculated cows. These results
were affirmed with the observation that clinical symptoms
appeared later and were milder in the plant-gDc vaccinated
animals (data not shown).
4. Discussion
We have demonstrated here that a plant viral based vector
can be used to produce sufficient quantities of an animal
viral antigen in crude plant extracts to be useful for effec-
tively immunizing animals against animal viral pathogens.
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Fig. 6. Cellular immune response induced in cattle to the plant-produced gDc. Lymphocyte-enriched cell cultures were prepared from PBMC at 80 dpi.
Blood cell samples were extracted from cattle immunized with crude foliar extracts from plants infected with TMV-gDc (bovines 41 and 49), TMV-30B
(animals 31 and 39), or from one animal injected with the BHV-1 conventional vaccine (conv. vac. #2). For each animal, triplicate cell cultures were
incubated with or without the specific BHV-1 antigen. Stimulation indexes in each case were determined as a ratio between the arithmetic means of
cultures with and without antigen (SI = 3 are considered positive).
Previously, we demonstrated that protective immunity could
be produced in mice injected with plant extracts containing
VP1 of foot-and-mouth disease virus expressed from the
same TMV vector [15]. Together, these two examples, using
two very different proteins derived from unrelated RNA and
DNA virus candidates, provide good evidence that animal
viral proteins expressed in plants retain sufficient structural
integrity to be useful for eliciting immunologically useful
responses in test animals.
First, our results showed quite convincingly that the TMV
vector carrying a cytoplasmic form of the glycoprotein D
subunit of bovine herpesvirus was able to direct the synthe-
sis of a protein of the expected electrophoretic mobility (ca.
55 kDa) and antigenic identity at concentrations estimated
in the range of 20g/g of fresh tissue. The protein appeared
to be stable in the plant extracts and slightly larger in size
than the E. coli-expressed gD. We assessed if the recombi-
nant plant-produced gDc retained a proper conformation by
testing its antigenic properties by performing a series of im-
munological experiments in both an animal model and the
natural host.
The antigenicity of the recombinant gDc was initially
studied in a murine model. A group of 10 animals received a
single dose of a vaccine formulated with crude extracts con-
taining approximately 2g of the plant-gDc. All the animals
developed a specific and sustained immune response against
both the gDc and the BHV-1, for up to 80 dpi. This response
was comparable to that registered for mice vaccinated with
the conventional immunogen, indicating that the plant-gDc
was immunogenic in mice and retained B-cell epitopes that
were also present in the native virus particle. Analysis of
the BHV-1-specific IgG isotype also demonstrated the pres-
ence of predominant levels of both IgG1 and IgG2a and to
a lesser extent IgG2b and IgG3 (data not shown). In con-
trast, animals immunized with the inactivated-virus vaccine
presented only significant levels of IgG1. These results indi-
cate the presence and functionality of T-cell epitopes in this
plant-produced gDc immunogen. This is consistent with the
high and persistent level of specific antibodies induced by
this protein.
Based on the positive results in mice, we then examined
the immune response induced by the plant-gDc in the natural
bovine host. Cattle were immunized using the same crude
immunogen, but they received a larger dose and a greater
number of booster doses because of the large size of the an-
imals. Both of the cows immunized with the gDc containing
plant extracts developed significant ELISA titers against
the recombinant gD-Ec by 40 dpi. This anti-gDc antibody
response strongly correlated with the specific anti BHV-1
humoral response measured at 50 dpi and the positive
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Fig. 7. Virus excretion in cows after challenge with infective BHV-1. Cattle were challenged at 210 dpi and the presence of infective virus in nasal
excretions was assessed for each animal. The titers obtained are presented separately for each animal, except for unvaccinated controls. Both panels:
the unvaccinated control results represent the mean titer (±S.D.) obtained from four animals. Panel A: animals vaccinated with the BHV-1 conventional
vaccines (animals 1–5) or with extracts from plants. Panel B: animals vaccinated with extracts from plants inoculated with TMV-30B (bovines 31 and
39) or TMV-gDc (bovines 41 and 49).
cellular immune response evaluated at 80 dpi. Moreover,
cattle immunized with the plant-produced gDc presented
good levels of protection to viral challenge. These results
were consistent with the observed cellular response, as it is
generally established that stimulation of the cellular immu-
nity plays a central role in the protection against the BHV-1
infection [27]. Both the emergence of symptoms and detec-
tion of virus in nasal excretions were significantly delayed
and shortened in these animals compared with controls. Im-
portantly, gDc-vaccinated cattle presented much less severe
symptoms and virus shedding in nasal fluids was reduced
by 2–4 logs in comparison with negative controls. Conven-
tionally vaccinated animals showed variable levels of pro-
tection, as previously reported [26]. While three of them did
not show significant virus shedding, the other two showed
an early detectable virus excretion. A most interesting re-
sult was that protection levels reached in cows immunized
with the plant-derived antigens—in terms of length, delay
and reduction of virus excretion—were similar to or even
better than some of animals that received the conventional
vaccine. Our results contrast with previous reports which
were unsuccessful at eliciting a level of protective response
as presented here when they used an unglycosylated form
of the BHV gD produced in E. coli [22].
This is the first report showing induction of protective an-
tibodies in cattle immunized with a plant-produced BHV-1
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antigen. In conclusion, we have now demonstrated that the
TMV-30B vector is suitable for production of proteins with
moderately high molecular weight such as gDc. The im-
munological characterization of the protein showed that a
significant part of the native gD conformation was retained
in the recombinant plant protein. These results, along with
those reported previously for FMDV demonstrate that a
structural protein of an RNA virus and an external mem-
brane protein of a DNA virus can be expressed in plants in
sufficient quantity and of sufficient quality to be useful for
eliciting protective antibodies in vaccinated animals. We rec-
ognize that that this relatively simple technology needs to be
further refined in order to be put into practice for production
of low cost and biologically safe animal vaccines. Although
optimization of the technology for commercial production of
useful vaccines utilizing this technology is beyond the scope
of this study, a recent report suggests that this goal could be
effectively accomplished through a commercial partnership
(personal communication, Greg Pogue, Large Scale Biol-
ogy Corporation). In this era of concern over the deliberate
release of animal pathogens for the purposes of bioterror-
ism, it would seem prudent for regulatory agencies to further
explore this relatively inexpensive approach for producing
agriculturally important vaccines.
Acknowledgements
We would like to thank Jill Hyslop and Marta Radolci for
excellent technical assistance.
References
[1] Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as
factories for biopharmaceuticals. Nat Biotechnol 2000;18:1151–5.
[2] Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill
LK. Production of recombinant proteins in plants: pharmaceutical
applications, The Soc. Exp. Biol., Canterbury, UK. J Exp Bot
1997;48(Suppl):12–21.
[3] Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines:
applications for prophylactic and therapeutic molecular medice.
Trends Mol Med 2002;8:324–9.
[4] Arakawa T, Chong DKX, Langridge WHR. Efficacy of a food plant
based oral cholera toxin B subunit vaccine. Nat Biotech 1998;16:
292–7.
[5] Mason HS, Lam DM-K, Arntzen CJ. Expression of hepatitis B
surface antigen in transgenic plants. Proc Natl Acad Sci USA
1992;89:11745–9.
[6] Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ.
Expression of Norwalk virus capsid protein in transgenic tobacco
and potato and its oral immunogenicity in mice. Proc Natl Acad Sci
USA 1996;93:5335–40.
[7] Gómez N, Carrillo C, Parra F, Salinas J, Borca MV, Escribano
JM. Expression of immunogenic glycoprotein S polypeptides
from transmissible gastroenteritis coronavirus in transgenic plants.
Virology 1998;249:352–8.
[8] Lacomme C, Smolenska L, Wilson TM. Genetic engineering and
the expression of foreign peptides or proteins with plant virus-based
vectors. In: Setlow JK, editor. Genetic Engineering. New York:
Plenum Press; 1998. p. 225–37.
[9] Johnson J, Lin T, Lomonosoff G. Presentation of heterologous
peptides on plant viruses: genetics, structure and function. Annu Rev
Phytopathol 1997;35:67–86.
[10] Scholthof HB, Scholthof K-BG, Jackson AO. Plant virus gene vectors
for transient expression of foreign proteins in plants. Annu Rev
Phytopathol 1996;34:299–323.
[11] Yusibov V, Shivprasad S, Turpen TH, Dawson W, Koprowski H. Plant
viral vectors based on tobacco mosaic viruses. Curr Top Microbiol
Immunol 1999;240:81–94.
[12] Kumagai MH, Turpen TH, Weinzettl N, della-Cioppa G, Turpen AM,
Donson J, et al. Rapid, high-level expression of biologically active
alpha-trichosanthin in transfected plants by an RNA viral vector.
Proc Natl Acad Sci USA 1993;90:427–30.
[13] McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill
LK, et al. Rapid production of specific vaccines for lymphoma by
expression of the tumor-derived single-chain Fv epitopes in tobacco
plants. Proc Natl Acad Sci USA 1999;96:703–8.
[14] Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill
LK. Malarial epitopes expressed on the surface of recombinant
tobacco mosaic virus. Biotechnology (NY) 1995;13:53–7.
[15] Wigdorovitz A, Perez Filgueira DM, Robertson N, Carrillo C, Sadir
AM, Morris TJ, et al. Protection of mice against challenge with
foot and mouth disease virus (FMDV) by immunization with foliar
extracts from plants infected with recombinant tobacco mosaic virus
expressing the FMDV structural protein VP1. Virology 1999;264:
85–91.
[16] Shivprasad S, Pogue GP, Lewandowski DJ, Hidalgo J, Donson
J, Grill LK, et al. Heterologous sequences greatly affect foreign
gene expression in tobacco mosaic virus-based vectors. Virology
1999;255:312–23.
[17] Kahrs RF. Infectious bovine rhinotracheitis: a review and update. J
Am Vet Med Assoc 1977;171:1055–64.
[18] Engels M, Ackerman M. Pathogenesis of ruminant herpesvirus
infections. Vet Microbiol 1996;53:3–15.
[19] Frerichs GN, Woods SB, Lucas MH, Sands JJ. Safety and efficacy
of live and inactivated infectious bovine rhinotracheitis vaccines. Vet
Rec 1982;111:116–22.
[20] Yates WD. A review of infectious bovine rhinotracheitis, shipping
fever pneumonia and viral-bacterial synergism in respiratory disease
of cattle. Can J Comp Med 1982;46:225–63.
[21] Babiuk LA, L’Italien J, van Drunen Littel-van den Hurk S,
Zamb T, Lawman JP, Hughes G, et al. Protection of cattle from
bovine herpesvirus type I (BHV-1) infection by immunization with
individual viral glycoproteins. Virology 1987;159:57–66.
[22] van Drunen Littel-van den Hurk S, Parker MD, Massie B, van den
Hurk JV, Harland R, Babiuk LA, et al. Protection of cattle from
BHV-1 infection by immunization with recombinant glycoprotein
gIV. Vaccine 1993;11:25–35.
[23] Zhu X, Wu S, Letchworth III GJ. Yeast-secreted bovine herpesvirus
type 1 glycoprotein D has authentic conformational structure and
immunogenicity. Vaccine 1997;15:679–88.
[24] Bosch JC, De Jong MC, Franken P, Frankena K, Hage JJ, Kaashoek
MJ, et al. An inactivated gE-negative marker vaccine and an
experimental gD-subunit vaccine reduce the incidence of bovine
herpesvirus 1 infections in the field. Vaccine 1998;16:265–71.
[25] Zamorano P, Taboga O, Dominguez M, Romera A, Puntel M, Tami
C, et al. BHV-1 DNA vaccination: effect of the adjuvant RN-205 on
the modulation of the immune response in mice. Vaccine 2002;20:
2656–64.
[26] Romera SA, Hilgers LA, Puntel M, Zamorano PI, Alcon VL, Dus
Santos MJ, et al. Adjuvant effects of sulfolipo-cyclodextrin in a
squalane-in-water and water-in-mineral oil emulsions for BHV-1
vaccines in cattle. Vaccine 2000;19:132–41.
[27] van Drunen Littel-van den Hurk S, Tikoo SK, Liang X, Babiuk LA.
Bovine herpesvirus-1 vaccines. Immunol Cell Biol 1993;71:405–20.
